Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study

被引:71
作者
Constantinides, C [1 ]
Manousakas, T [1 ]
Nikolopoulos, P [1 ]
Stanitsas, A [1 ]
Haritopoulos, K [1 ]
Giannopoulos, A [1 ]
机构
[1] Univ Athens, Sch Med, Laikon Gen Hosp, Dept Urol 1, GR-11527 Athens, Greece
关键词
recurrent urinary tract infection; hyaluronic acid; bladder instillations; glycosaminoglycans;
D O I
10.1111/j.1464-410X.2004.04850.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
OBJECTIVES To assess the effect of bladder instillations of hyaluronic acid (HA) on the rate of recurrence of urinary tract infection (UTI). PATIENTS AND METHODS Forty women (mean age 35 years) with a history of recurrent UTI received intravesical instillations of HA (40 mg in 50 mL phosphate-buffered saline) once weekly for 4 weeks then once monthly for 4 months. The UTI status was assessed over a prospective follow-up of 12.4 months and compared with the rates of UTI before instillation, determined by a retrospective review of patient charts covering 15.8 months. RESULTS After HA treatment no patients had a UTI during the 5-month treatment phase and 28 (70%) were recurrence-free at the end of the follow-up. The mean (SD) rate of UTI per patient-year was 4.3 (1.55) before treatment and 0.3 (0.55) afterward (P < 0.001). The median time to recurrence after HA treatment was 498 days, compared with 96 days beforehand (P < 0.001). The tolerability was excellent, as side-effects were limited to nine patients who reported mild bladder irritation; no patient interrupted the treatment. CONCLUSIONS In this preliminary study, bladder instillations of HA had a significant effect on the rate of UTI in women with a history of recurrent UTIs. The bladder instillation of HA is an acceptable and promising therapeutic alternative in patients with recurrent UTI. Expanded placebo controlled clinical trials examining this application of HA are currently underway.
引用
收藏
页码:1262 / 1266
页数:5
相关论文
共 31 条
[1]
Comparative assessment of maximal bladder capacity, 0.9% NaCl versus 0.2 M KCl, for the diagnosis of interstitial cystitis:: A prospective controlled study [J].
Daha, LK ;
Riedl, CR ;
Hohlbrugger, G ;
Knoll, M ;
Engelhardt, PF ;
Pflüger, H .
JOURNAL OF UROLOGY, 2003, 170 (03) :807-809
[2]
A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women [J].
Eriksen, BC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (05) :1072-1079
[3]
Foxman B, 2000, AM J EPIDEMIOL, V151, P1194, DOI 10.1093/oxfordjournals.aje.a010170
[4]
Foxman B, 2002, AM J MED, V113, p5S
[5]
Urinary tract infection: Self reported incidence and associated costs [J].
Foxman, B ;
Barlow, R ;
D'Arcy, H ;
Gillespie, B ;
Sobel, JD .
ANNALS OF EPIDEMIOLOGY, 2000, 10 (08) :509-515
[6]
Pathogenesis and management of recurrent urinary tract infections in women [J].
Gupta, K ;
Stamm, WE .
WORLD JOURNAL OF UROLOGY, 1999, 17 (06) :415-420
[7]
Analysis of long-term Elmiron therapy for interstitial cystitis [J].
Hanno, PM .
UROLOGY, 1997, 49 (5A) :93-99
[8]
Recurrent urinary tract infection in women [J].
Hooton, TM .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 17 (04) :259-268
[9]
Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P552
[10]
INACTIVATION OF ANTIADHERENCE EFFECT OF BLADDER SURFACE GLYCOSAMINOGLYCANS AS POSSIBLE MECHANISM FOR CARCINOGENESIS [J].
KAUFMAN, JE ;
ANDERSON, K ;
PARSONS, CL .
UROLOGY, 1987, 30 (03) :255-258